Reversal of novel oral anticoagulants
Oral anticoagulants are commonly prescribed for the prevention and treatment of thromboembolic disorders. Coagulopathy is an inherent risk for all anticoagulants, and data regarding reversal of newer agents are sparse. Unlike warfarin, limited options currently exist for rapid reversal of novel oral anticoagulants (direct thrombin inhibitors, factor Xa inhibitors) and include fresh frozen plasma and prothrombin complex concentrates. While no true antidote is yet available, several promising agents are in development. As a result, healthcare providers, principally pharmacists, must be prepared to appropriately monitor and manage patients requiring reversal. Â© 2000 - 2015 Jobson Medical Information LLC unless otherwise noted.All rights reserved.
Lee, Winnie; Patel, Deepa V.; and Lisi, Dusty L., "Reversal of novel oral anticoagulants" (2015). PCOM Scholarly Papers. 1137.
This document is currently not available here.